CA Patent

CA2592177A1 — Fixed dosing of her antibodies

Assigned to Genentech Inc · Expires 2006-07-27 · 20y expired

What this patent protects

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

USPTO Abstract

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

Drugs covered by this patent

lazertinib-mesylate (LAZERTINIB MESYLATE)

Patent Metadata

Patent number: CA2592177A1
Jurisdiction: CA
Classification: —
Expires: 2006-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.